Pipeline

DKN-01:Anti-DKK1 antibody

tislelizumab + chemotherapy

Preclinical

Phase 1

Phase 2

Phase 3

• Gastric

DKN-01:Anti-DKK1 antibody

bevacizumab + chemotherapy

Preclinical

Phase 1

Phase 2

Phase 3

• Colorectal

DKN-01:Anti-DKK1 antibody

pembrolizumab

Preclinical

Phase 1

Phase 2

Phase 3

• Endometrial

FL-301 (NBL-015):Anti-CLDN18.2 antibody

Preclinical

Phase 1

Phase 2

Phase 3

• Gastric
• Pancreatic

FL-501:Anti-GDF-15 antibody

Preclinical

Phase 1

Phase 2

Phase 3